CytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have received a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $5.77.

Separately, HC Wainwright restated a “neutral” rating on shares of CytomX Therapeutics in a report on Friday, September 13th.

Institutional Investors Weigh In On CytomX Therapeutics

Several large investors have recently added to or reduced their stakes in CTMX. US Bancorp DE acquired a new position in shares of CytomX Therapeutics in the third quarter worth $40,000. Assenagon Asset Management S.A. grew its stake in CytomX Therapeutics by 32.8% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,644,168 shares of the biotechnology company’s stock worth $1,940,000 after purchasing an additional 405,669 shares in the last quarter. Congress Park Capital LLC increased its holdings in CytomX Therapeutics by 5.4% during the 3rd quarter. Congress Park Capital LLC now owns 1,216,008 shares of the biotechnology company’s stock worth $1,435,000 after purchasing an additional 62,788 shares during the period. Cubist Systematic Strategies LLC raised its position in CytomX Therapeutics by 96.6% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 82,054 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 40,309 shares in the last quarter. Finally, Forefront Analytics LLC boosted its stake in shares of CytomX Therapeutics by 206.7% in the 2nd quarter. Forefront Analytics LLC now owns 64,065 shares of the biotechnology company’s stock valued at $78,000 after buying an additional 43,176 shares during the period. 67.77% of the stock is owned by hedge funds and other institutional investors.

CytomX Therapeutics Trading Up 0.7 %

CTMX opened at $1.00 on Thursday. CytomX Therapeutics has a twelve month low of $0.98 and a twelve month high of $5.85. The firm has a market capitalization of $78.12 million, a PE ratio of 7.14 and a beta of 1.06. The firm’s 50-day moving average price is $1.14 and its 200 day moving average price is $1.48.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The firm had revenue of $25.12 million during the quarter, compared to analysts’ expectations of $21.79 million. CytomX Therapeutics had a net margin of 9.27% and a negative return on equity of 27.44%. During the same period in the prior year, the company posted ($0.02) EPS. As a group, analysts predict that CytomX Therapeutics will post -0.29 earnings per share for the current fiscal year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.